Company intelligence / Profile preview
CytoCares
- Ownership
- Private
- Development stage
- Other
Overview
CytoCares is a Shanghai-based immuno-oncology biotech developing first-in-class multi-specific antibody therapeutics. Its lead asset, CC312, is a trispecific antibody currently in Phase 1 trials targeting relapsed/refractory CD19-positive B-cell malignancies. The company also recently received IND approval in China to begin clinical studies of CC312 for systemic lupus erythematosus. Proprietary platforms target T cells, NK cells, and tumor-associated macrophages to stimulate anti-tumor immunity or modulate immune responses.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Multi-specific antibodies (including trispecific T-cell engagers)Antibody therapeutics targeting immune cells (T cells, NK cells, macrophages)
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on CytoCares.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoCares.